We aim to enable exceptional scientific outcomes by commercializing transformative products for researchers to unlock deep, unbiased biological information. Our initial product, the Proteograph Product Suite (Proteograph), will leverage our proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access across the proteome.
Proteins are the functional units of all forms of life. The proteome is the entire set of proteins that is or can be expressed by a genome, cell, tissue or organism at a certain time. The genome is the total of an organism’s DNA. Despite the central role proteins play in biology, the proteome is relatively unexplored compared to the genome.
Our technology is designed to capture and translate molecular insights from the proteome to enable early detection of cancer and neurological disease and drive earlier treatment to improve patient outcomes. The goal is to develop first-in-class liquid biopsy products to detect diseases at early pre-symptomatic stages.
(Note: The Seer IPO was upsized at pricing: 9.21 million shares at $19, up from 8.8 million shares at $16 to $18 in the prospectus.)
|Industry:||Laboratory Analytical Instruments|
|Address||3800 Bridge Parkway, Suite 102 Redwood City, California 94065|
|View Prospectus:||Seer, Inc.|
|Revenues||$0.38 mil (last 12 months)|
|Net Income||$-24.99 mil (last 12 months)|
|Price range||$19.00 - $19.00|
|Est. $ Volume||$175.0 mil|
|Manager / Joint Managers||J.P. Morgan/ Morgan Stanley/ BofA Securities/ Cowen and Company|
|Expected To Trade:||12/4/2020|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|